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Abstract 
The term oral cavity cancer (OSCC) constitutes cancers of the mucosal surfaces of the lips, floor of mouth, oral 
tongue, buccal mucosa, lower and upper gingiva, hard palate and retromolar trigone. Treatment approaches for 
OSCC include single management with surgery, radiotherapy [external beam radiotherapy (EBRT) and/or brachy-
therapy], as well as adjuvant systemic therapy (chemotherapy and/or target agents); various combinations of these 
modalities may also be used depending on the disease presentation and pathological findings. The selection of sole 
or combined modality is based on various considerations that include disease control probability, the anticipated 
functional and cosmetic outcomes, tumor resectability, patient general condition, and availability of resources and 
expertise. For resectable OSCC, the mainstay of treatment is surgery, though same practitioners may advocate for 
the use of radiotherapy alone in selected “early” disease presentations or combined with chemotherapy in more 
locally advanced stage disease. In general, the latter is more commonly reserved for cases where surgery may be 
problematic. Thus, primary radiotherapy ± chemotherapy is usually reserved for patients unable to tolerate or who 
are otherwise unsuited for surgery. On the other hand, brachytherapy may be considered as a sole modality for 
early small primary tumor. It also has a role as an adjuvant to surgery in the setting of inadequate pathologically 
assessed resection margins, as does postoperative external beam radiotherapy ± chemotherapy, which is usually 
reserved for those with unfavorable pathological features. Brachytherapy can also be especially useful in the re-
irradiation setting for persistent or recurrent disease or for a second primary arising within a previous radiation 
field. Biological agents targeting the epithelial growth factor receptor (EGFR) have emerged as a potential moda-
lity in combination with radiotherapy or chemoradiotherpy and are currently under evaluation in clinical trials. 
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Introduction
In epidemiology studies, the term ‘oral cancer’ is some-
times employed to connote both oral cavity cancer and 
oropharyngeal cancer. However, these are different 
clinical entities and in contemporary practice often have 
different etiologies and are frequently managed differ-
ently. The latter largely occurs for reasons that pertain 
to local anatomy, functional outcome, and long-term 
toxicity, especially bone. This review will embrace the 
clinical definition of “oral cancer”, as defined by the 
American Joint Committee on Cancer (AJCC) and the 
Union for International Cancer Control (UICC) in the 
tumor-node-metastasis (TNM) staging classification. 
This includes squamous cell carcinomas of the oral cav-
ity (OSCC) originating from the mucosal lip, anterior 
two-thirds of the tongue (oral tongue), buccal mucosa, 
floor of mouth, hard palate, lower and upper alveolus 
and gingiva, and the retromolar trigone.  
Treatment of OSCC includes single modality surgery, 
radiotherapy [external beam radiotherapy (EBRT) and/
or brachytherapy], or various combinations of these mo-
dalities with or without systemic therapy (chemother-
apy and/or target agents). The selection of treatment is 
based on considerations of disease control, anticipated 
functional and cosmetic outcomes, and availability of 
resources and expertise. From a practical stand-point, 
the availability of reports largely dictates that we need 
to rely on retrospective case series and a few available 
randomized trials and several combined analysis that 
include meta-analysis data.
The mainstay of treatment for OSCC is usually surgery 
(1). EBRT with or without chemotherapy is generally 
employed in 3 situations: a) adjuvant to primary surgery 
to enhance loco-regional control (LRC) for cases with 
unfavorable pathological features,  b) primary treatment 
for cases unable to tolerate or unsuited for surgery, and 
c) salvage treatment in the persistent or recurrent dis-
ease setting. Brachytherapy may be employed as a sole 
modality for early disease with a well-defined primary 
tumor, or as an adjuvant to surgery for cases with close 
or positive resection margins. Alternatively it may be 
used as a “boost” technique to the primary tumor in 
addition to EBRT (Table 1). Recently, epithelial grown 
factor receptor (EGFR) targeted therapy, such as ce-
tuximab, has emerged as a promising treatment option 
in conjunction with EBRT to enhance disease control. 
 External Beam 
Radiotherapy (EBRT) 
Chemotherapy Interstitial Brachytherapy 
Primary setting ? Early disease when patient 
intolerant of surgery 
? Early disease when 
anticipated cosmetic 
consequence of surgery is a 
concern, especially for lip 
cancer involving 
commissure 
? Unresectable disease, 
usually combined with 
chemotherapy 
? Advanced disease for 
patients intolerant of surgery 
due to poor performance 
status or comobidities 
? Advanced disease or 
unresectable disease, 
in combination with 
radiotherapy 
? Early and superficial well-
defined tumor located 
more than 5 mm from the 
mandible
Adjuvant setting ? Unfavorable pathological 
features 
? Combined with 
chemotherapy for positive 
resection margins and 
extracapsular nodal 
extension  
? Combined with 
radiotherapy for 
positive resection 
margins or 
extracapsular nodal 
extension 
? Brachytherapy alone for 
positive resection margins 
? In combination with 
external beam radiotherapy 
to augment radiotherapy 
dose to the high risk area 
Salvage setting ? Adjuvant treatment after 
salvage surgery 
? Primary treatment modality, 
usually combined with 
chemotherapy if further 
surgery is not feasible 
? Combined with 
radiotherapy 
? Especially useful for re-
irradiation:  
? for persistent or 
recurrent disease after 
previous radiation,  
? 2nd primary cancer 
occurrence within 
previous radiation field 
Table 1. Summary of Role of Radiotherapy and Chemoradiotherapy in Oral Cavity Cancer.
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Postoperative Radiotherapy ± Chemotherapy
-Risk profile and indications for adjuvant treatment
Primary surgery is the traditional approach for resect-
able OSCC in most centers. For patients with unfavour-
able pathological features, postoperative radiotherapy 
(PORT) or postoperative concurrent chemo-radiother-
apy (POCRT) have been shown to improve LRC and 
survival in several clinical trials (2-4). General indi-
cations for PORT include: T3 or T4 tumor; comprom-
ised surgical resection margins (<5 mm from the inked 
surface of the specimen); presence of lympho-vascular 
invasion (LVI) and/or peri-neural invasion (PNI); and 
positive lymph nodes with or without extracapsular in-
vasion (ECE) (2,5). 
The presence of multiple risk factors is common in 
OSCC. To understand the loco-regional recurrence risk 
profile, Langendijk, et al. studied 801 head-and-neck 
cancer patients (73% of whom had OSCC) who under-
went PORT in 1985-2000. They did not include their 
most favourable cases that did not require PORT in the 
report. A recursive partitioning analysis addressing 
loco-regional recurrence stratified patients into three 
risk groups: a) intermediate-risk: clear resection mar-
gins and no ECE, b) high-risk: T1, T2 and T4 tumor 
with close or positive margins or one pathological posi-
tive lymph node with ECE, c) very high-risk: T3 tumor 
with close or positive surgical margins or multiple 
pathological positive lymph nodes with ECE or an N3 
neck (6).  For the latter two groups, the 5-year LRC with 
PORT was unsatisfactory (78% and 58%, respectively). 
The authors concluded that more intensive approaches, 
such as POCRT with concurrent chemotherapy should 
be considered for these two sub-groups. 
Pathological stage I-II disease with sufficiently clear 
resection margins is generally considered low-risk and 
does not require PORT (7). Studies suggest that PNI 
alone appears to be non-predictive for recurrence (8,9). 
However, the presence of LVI or microscopic tumor foci 
in muscle increased the risk of recurrence and PORT 
should be considered. Tumor thickness, or alternative 
synonyms such as “depth of invasion” or “tumor depth”, 
has been consistently identified as a predictor for cer-
vical lymph node metastasis (10). Recent studies have 
shown that pathological tumor thickness ≥ 4 mm com-
bined with poorly differentiated pT1-2N0 OSCC tumors 
are associated with poor regional control and such pa-
tients may benefit from PORT (11). 
The effectiveness of PORT for T1 or T2 primary with com-
pletely resected N1 disease is yet to be confirmed. Current-
ly, there is an on-going European clinical trial evaluating 
the effectiveness of PORT in pT1-T2pN1 oral cavity and 
oropharyngeal cancers with clear resection margins (12).
The presence of microscopic positive margins and/or 
ECE is considered high-risk for recurrence. The addi-
tion of chemotherapy to PORT for these patients resulted 
in a 13% absolute reduction in loco-regional relapse at 
5-years in the EORTC trial 22931 reported by Bernier 
et al. (13) and a 10% absolute reduction at 2-years in the 
RTOG trial 9501 reported by Cooper, et al. (3). Other 
features may also be considered “high-risk”. The RTOG 
85-03 and 88-24 trials indicated the presence of 2 or 
more pathological positive lymph nodes as a high-risk 
feature for loco-regional failure (14). Some studies have 
also shown that multiple (> 2) minor risk factors com-
bined with LVI were associated with poor prognosis 
(15-17) suggesting that more intensive regimens such as 
concurrent chemotherapy, may be justified in addition 
to PORT (Fig. 1). 
-Definition of close resection margin
The definition of ‘close’ resection margins is generally 
accepted as tumor within 5 mm of the inked resection 
margin in formalin fixed surgical specimens (18). Sev-
eral small retrospective studies suggested that the trad-
itional margin of 5 mm may be too generous, especially 
when one consider the shrinkage that take place in the 
final surgical specimen; this may amount to as much 
as 40%~50% compared to fresh specimens (19). These 
authors suggested that a 2 mm inked margin as “cutoff” 
for the “close” margin definition is sufficient (20,21). 
However, these findings are based on small retrospect-
ive studies and need confirmation.  
The risk associated with an intra-operatively ‘revised’ 
margin following a positive resection margin excision 
has not been well studied. Compromised local control 
and disease-specific survival for those with intra-opera-
tive positive margin was described recently even though 
the final tumor margin was negative after revision (22). 
The latter study supports the adverse nature of an intra-
operative positive margin regardless of final tumor mar-
gin, and PORT should be considered. 
-Optimal surgery-to-radiotherapy interval
The optimal surgery-to-radiotherapy interval is con-
troversial. A systematic review of published literature 
showed an increased odds ratio (2.9) for local recur-
rence in head and neck cancer patients whose PORT 
were started more than 6 weeks after surgery vs. those 
within 6 weeks of surgery (23). The optimal nature of a 
surgery-to-radiotherapy interval of “6 weeks” was also 
echoed in a recent OSCC series (24) but not confirmed 
by others (5,25). Nevertheless, commencing PORT as 
soon as possible seems desirable but requires careful 
planning and multidisciplinary collaboration, and may 
not always be achievable when surgical complications 
are present. Furthermore, such complications are more 
likely following larger and more extensive surgical re-
section for more locally invasive lesions, larger tumors, 
and those with extensive lymph node involvement. Pa-
tients with such tumors are more likely to be candidates 
for intensive adjuvant treatments and the most likely to 
suffer from their omission. The greater prevalence of 
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more advanced cancer in the latter time cohort due to 
wound healing delay may also partly explain any puta-
tive adverse influence of delay in the initiation of PORT. 
Therefore, no arbitrary time limit has been scientifically 
established during which PORT must begin, or beyond 
which PORT has been shown not to have an effect (5). 
In essence, high risk cases should still be considered 
in circumstances where there has been delay in initiat-
ing radiotherapy due to the grave consequences of loco-
regional recurrence that might be prevented by the use 
of adjuvant treatment.    
Primary Radiotherapy ± Chemotherapy with-
out Surgery
Primary radiotherapy with or without chemotherapy is 
not used routinely but may be deployed for the follow-
ing reasons: a) in early stage disease to avoid anticipated 
functional and cosmetic defect, b) for unresectable dis-
ease, c) for high operative risk patients due to comor-
bidity or poor performance status, d) recurrent disease 
when previous multiple surgeries have been undertaken 
and further surgery would be technically improbable, 
and e) patient’s preference. No prospective trial has dir-
ectly compared primary surgery vs. primary radiother-
apy in OSCC specifically. Two case series comparing 
RT vs. surgery suggested a lower LRC with primary 
radiotherapy compared to surgery approach (26,27). 
However, these patients were mostly treated with less 
intensified treatment regimens and the retrospective 
nature of the studies questions whether case selection 
for both treatments was equal. Also, whether intensi-
fied treatment approaches, such as concurrent chemo-
radiotherapy, could improve outcome sufficiently to be 
 
Oral Cavity  
Squamous Cell Carcinoma 
Intermediate-risk (any): 
? T3-T4 
? Close resection margin 
? LVI 
? PNI 
? Positive lymph node(s) 
without ECE
High-risk (any): 
? Positive resection 
margin 
? ECE 
Treatment: 
? PORT 
 
Expected Outcome:
? 5-year LRC: ~78% 
? Treatment effect size:  
(PORT vs. Surgery alone) 
-30% difference in DFS 
-10% difference in OS but 
NS
Treatment: 
? POCRT 
 
Expected Outcome:
? 5-year LRC: ~80% 
? Treatment effect size:  
(POCRT vs. PORT) 
-28% difference in OS 
-42% difference in LRC 
?
Treatment: 
? Surgery alone 
 
Expected Outcome:
? 5-year LRC: >90%  
(Only retrospective data 
available) 
Low-risk (all):
? T1-T2 
? Clear resection margin (?5 
mm) 
? no LVI  
? no microscopic muscle 
invasion 
Fig. 1. Summary of Risk Grouping and Role of Postoperative Radiotherapy +/- Chemotherapy.
Abbreviations: LVI: lympho-vascular invasion; ECE: extra-capsular invasion; PORT: postoperative radiotherapy; POCRT: 
postoperative chemoradiotherapy; LRC: locoregional control; DFS: disease-free survival; OS: overall survival; NS: not statisti-
cal significant
Note:
1. Crude estimates of expected outcomes were obtained from the following sources: 
• Low-risk: Huang, et al. (8)
• Intermediate-risk: Langendjk, et al. (25), 
• High-risk: Bernier, et al. (2) from the experimental arms of the combined report of RTOG #9501 and EORTC #22931 
2. Treatment effect size: 
• PORT vs. Surgery: Mishra, et al (55)
• POCRT vs. PORT: Bernier, et al (2)
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comparable to surgery remains to be investigated. A 
subgroup analysis of 39 T4 OSCC with primary CRT 
from four multi-institutional phase II studies showed a 
5-year LRC rate of 75% (28); in turn this opens the po-
tential for organ preservation approaches with CRT in 
patients with T4 OSCC.  
In the meta-analysis of individual patient data from 
clinical trials comparing RT vs. CRT (MACH-NC) in 
locally advanced head and neck cancers, OSCC com-
prised 21% of cases (29). Result showed an improve-
ment of survival in OSCC with CRT compared to RT 
alone (HR =0.8). In the meta-analysis of individual pa-
tient data from clinical trials comparing hyper-fraction-
ated or accelerated vs. conventional radiotherapy sched-
ule (MARCH) (30), OSCC consisted of only 12.6% of 
cases. Again, intensified regimens, in this case altered 
fractionation radiotherapy, improved survival over con-
ventional radiotherapy (hazard ratio = 0.8) . The results 
from these two meta-analyses seem to suggest that for 
patient unable to receive primary surgery, treatment 
intensification by concurrent chemotherapy or altered 
fractionation RT may be considered. 
Interstitial Radiotherapy (Brachytherapy)
Interstitial brachytherapy represents a traditional ap-
proach for OSCC and is an alternative to external beam 
radiotherapy (EBRT). Brachytherapy delivers radiother-
apy by positioning radioactive sources in direct proximity 
to the tumor target area. The advantage of brachytherapy 
is its highly conformal dose distribution to a small target 
area by virtue of a rapid “fall-off” within surrounding 
normal tissue. It can be applied as a definitive treatment 
for early OSCC; as a complimentary treatment in com-
bination with surgery; as a local “boost” in combination 
with EBRT to enhance the local dose to the immediate 
tumor region; or as a salvage option for small burden per-
sistent or recurrent disease (31). 
-Brachytherapy alone
No randomized trials have been performed comparing 
brachytherapy versus other conventional treatment for 
OSCC. Based on clinical experience, a consensus state-
ment from GEC-ESTRO has recommended that brachy-
therapy alone could be used for T1-T2N0 oral mucosa 
(<1.5 cm in thickness), oral tongue lesion, or floor of 
mouth lesions locate at least 5 mm from the mandible 
due to the high risk of inducing osteoradionecrosis 
(ORN). Brachytherapy is not suitable for T4 tumor 
with bone involvement (31). An additional concern 
about the use of brachytherapy alone for early OSCC is 
its inability to addressing occult neck disease. For ex-
ample, an increased rate of late lymph node recurrence 
for clinical T1N0 OSCC has been reported following 
brachytherapy alone, especially in tumors exceeding 6 
mm in thickness.  The authors have consequently rec-
ommended prophylactic nodal irradiation in addition 
to brachytherapy for early-stage OSCC exceeding this 
thickness (32). 
-Postoperative brachytherapy
Postoperative brachytherapy could be offered in T1-3 
tumor with narrow or positive resection margins or LVI. 
A retrospective study of local tumor excision followed 
by postoperative interstitial brachytherapy with and 
without external radiotherapy has shown excellent loco-
regional control (33). In addition, brachytherapy can be 
delivered as an adjuvant “boost” to augment the radia-
tion dose to a high risk area for advanced OSCC under-
going EBRT (34-37).  An alternative approach is the use 
of simultaneous integrated boost IMRT but the relative 
value of both approaches remains to be determined. 
Brachytherapy for re-irradiation
The feasibility of re-irradiation with EBRT after de-
finitive EBRT is limited by concerns about excessive 
morbidity related to normal tissue tolerance. Therefore, 
surgical resection is often and appropriately presented 
as the main or potentially only curative option.  How-
ever, carotid involvement in persistent disease is rela-
tively common in recurrent disease and carotid artery 
resection carries significant risk including potential 
dramatic adverse sequelae, such as cerebrovascular 
event. Because of the ability to curtail the size of the ir-
radiated volume, brachytherapy seems especially indi-
cated to minimize the risk of severe complications in 
re-irradiation for persistent/recurrent disease or for new 
primary tumors located within previously irradiated 
volumes (33,38,39). 
-Brachytherapy delivery techniques
Commonly used radioactive sources are I-125 and Ir-
192. Considerable experience has been accumulated 
with low-dose rate (LDR) brachytherapy and its effect-
iveness for OSCC has been confirmed in large clinical 
series (40). Recently, high-dose rate (HDR) and pulsed-
dose rate (PDR) brachytherapy have emerged as new 
brachytherapy delivery techniques offering the advan-
tage of optimizing dose distribution by varying dwell 
times and employing computerized planning and deliv-
ery techniques. However, these techniques require the 
availability of particular expertise and resources that 
has affected their widespread adoption in many centers 
especially in settings with insufficient operating room 
resources and radiotherapy protection requirements. 
Biotherapy with Targeted Agent
Emerging data also indicate that the epidermal growth 
factor (EGFR) and its signal transduction pathway 
play an important role in head and neck cancer. Over-
expression of EGFR has been confirmed in OSCC and 
has been reported to be associated with a poor progno-
sis (41-43). The addition of a targeted agent, such as a 
monoclonal antibody EGFR inhibitor, has been reported 
to improve outcome over primary radiotherapy alone in 
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head and neck cancers of the oropharynx, hypopharynx 
and larynx (44). Its role in OSCC has yet to be con-
firmed. Recently, the RTOG 0920 trial was launched to 
address intermediate-risk (PNI, LVI, close margin, T3 
or T4a tumor, T2 with > 5mm thickness, single lymph 
node > 3 cm or ≥ 2 lymph node < 6 cm without ECE) 
OSCC patients to evaluate whether the addition of ce-
tuximab to PORT will improve overall survival (OS) in 
postoperative patients.
Radiation-related Toxicity ± Chemotherapy
Radiotherapy with or without chemotherapy to enhance 
disease control is associated with radiation-induced 
toxicity. The acute toxicity includes grade 2/3 oral mu-
cositis and dysphagia. The incidence is generally high, 
especially with bilateral irradiation, though is usually 
self-limiting (45). Common late toxicities include ORN, 
xerostomia, and dysphagia (46). The general impression 
of practitioners is that toxicity is enhanced by the use of 
concurrent chemotherapy with PORT.  For example, the 
combined severe acute and late toxicity frequency in the 
RTOG trial 9501 reported by Cooper, et al. (3) amounted 
to 46% vs. 78% for PORT vs. POCRT respectively. For 
reasons that are not immediately apparent, the toxicity 
profile seems less clear in EORTC 22931; for example 
the severe muscular fibrosis rate was higher for POCRT 
(10% vs. 5%) but severe xerostomia was lower (14% 
vs. 22%) (13). These observations underline the need 
to prospectively include comprehensive toxicity data 
collection in future trials. Spontaneous ORN is dose-
dependent and related to the volume of mandible receiv-
ing radiotherapy beyond 50~60 Gy (47). The incidence 
is generally low (<15%) with conventional conformal 
radiotherapy (48) with the exception of one unexpected 
retrospective report in the recent literature (49). Intensi-
ty modulated radiotherapy (IMRT) is a newer method of 
radiotherapy that uses intensity-modulated beams that 
can provide multiple intensity levels allowing concave 
dose distributions and dose gradients with narrower 
margins than those possible using traditional radiother-
apy (50) (Fig. 2). The incidence of ORN can be further 
reduced significantly by minimizing the percentage of 
mandibular volume exposed to >50~60 Gy using IMRT 
(47,51,52). In addition, careful oral dental hygiene and 
smoking cessation are also important for preventing 
ORN. Xerostomia rates are high with conventional 
Huang SH & O’Sullivan B - REF.18772 
A. Conventional 3D-conformal Radiotherapy B. Intensity-modulated Radiotherapy (IMRT) 
Primary tongue tumor
50 Gy Isodose Line
Parotid Gland 
Parotid Gland 
50 Gy Isodose Line 
60 Gy Isodose Line 
60 Gy Isodose Line 
Fig. 2. Example of partial mandible and parotid-sparing IMRT vs. conventional 3D-conformal radiotherapy.
Note: 
  •Two actual cases of T4aN0 oral tongue cancer. The dose prescription is 70 Gy in 35 fractions in both cases
  •White arrows indicate radiation beam arrangement: 
  • Conventional radiotherapy: two lateral beams: 90° and 270°
  • IMRT: equally spaced 9 beam plan configuration: 200°, 240°, 280°, 320°, 0°, 40°, 80°, 120°, 160°
  •For the same stage of disease, IMRT is able to partially spare the ipsi-lateral and totally spare the contra-lateral mandible and 
parotid gland to receive 60 Gy; while both side of mandibles and almost both parotid glands received >60 Gy in conventional 
3D-conformal radiotherapy. 
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radiotherapy when salivary gland and oral cavity mu-
cosa are inevitably included in the radiation field. IMRT 
has demonstrated an ability to enhance salivary spar-
ing to reduce the rate of permanent xerostomia without 
compromising disease control (45,53). It is also capable 
of reducing the rate of severe dysphagia compared to 
conventional radiotherapy (54). 
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